BMC Ophthalmology (Sep 2022)

Modified argon laser therapy for benign tumor of the eyelid

  • Jisang Han,
  • Shin-Hyo Lee,
  • Chul Young Choi,
  • Ramin Khoramnia,
  • Jaemin Kim,
  • Hyun Jin Shin

DOI
https://doi.org/10.1186/s12886-022-02601-w
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Background To report about the therapy of benign eyelid tumors with a modified argon laser technique as an alternative to surgery. Methods Nineteen benign tumors of the eyelid were included in this study. After staining the surface of the tumor with a violet marker, low-energy argon laser photoablation was performed. A mean number of 312 spots (spot size ranging from 150 to 500 μm) with a power of 200 to 400 mW, and a duration between 0.1 and 0.2 s were applied. Results The eyelid tumors were located mainly in the lower eyelid (58%). Dermal nevi and papilloma were the most frequently treated lesions. Over a mean follow-up period of 10.5 months (range 6–18 months), all eyelid tumors were successfully treated by a single session of laser therapy. All patients were satisfied with the laser therapy and the cosmetic result. No postoperative complications were observed. No relapses occurred during follow-up. Conclusions Our modified method of argon laser therapy utilizes the staining of the surface of the eyelid tumor to increase the amount of thermal laser energy absorbed by the target. This novel technique is simple and effective for treating benign eyelid tumors.

Keywords